



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Mary F. Fitzgerald, et al.

Group Art Unit: 1624

Serial No.: 09/869,668

Examiner: Patel, Sudhaker B.

Filed: 01/02/2002

For: Use of Substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives as Matrix Metalloprotease Inhibitors for the Treatment of Respiratory Diseases

MAIL STOP ISSUE FEE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Mail Stop ISSUE FEE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: JUN 01 2004

Signature of person certifying [Jill Durante]

ISSUE FEE
TRANSMITTAL LETTER

Sir:

Enclosed please find the following documents in connection with transmittal and payment of the issue fee in the above-identified case:

- Part B - Issue Fee Transmittal (Form PTOL-85B) (IN DUPLICATE);
- Amendment Pursuant to 37 C.F.R. § 1.312; and
- Return Receipt Post Card.

Respectfully submitted,

Date: JUN 01 2004

William F. Gray
Attorney for Applicants
Reg. No. 31,018

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175
Telephone: (203) 812-2712
Facsimile: (203) 812-6459